Impact Therapeutics
Latest round
- Series D
Last raised
- Apr 2024
Total raised
- $145M
Investors
- 22
About Impact Therapeutics
, dba Impact Therapeutic, is a drug developer dedicated to developing new targeted anti-cancer drugs with independent intellectual property rights. It has a sub-branch office in Shanghai. The CEO of the company, Dr. Sui Xiong Cai graduated from the University of Oregon. The CSO of the company, Dr. Ye Edward Tian graduated from the Michigan State University and has new drug R&D experience in pharmaceutical companies and biotechnology companies.1 per share at Hong Kong Stock Exchange, under the ticker "7630". The company focuses on synthetic lethal mechanisms of action that can kill cancer cells with certain mutations, such as defects in DNA damage repair. It mainly develops DNA damage response (DDR) product portfolio. The company's pipeline includes PARP inhibitor (Senaparib/IMP4297), Wee1 inhibitor (IMP7068), and multiple other DDR target inhibitors. PARP inhibitors are used in ovarian cancer, prostate cancer, small cell lung cancer and other diseases. The company generates revenue by developing and delivering drugs to treat cancer and other life-threatening diseases.
Who invested in Impact Therapeutics
22 investors across 6 rounds
See all investors in Impact Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Impact Therapeutics
Who invested in Impact Therapeutics?
Impact Therapeutics has 22 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Impact Therapeutics raised?
Impact Therapeutics has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Impact Therapeutics last raise money?
Impact Therapeutics's most recent round on record is a Series D, in Apr 2024.
What does Impact Therapeutics do?
, dba Impact Therapeutic, is a drug developer dedicated to developing new targeted anti-cancer drugs with independent intellectual property rights.
Where is Impact Therapeutics headquartered?
Impact Therapeutics is headquartered in Nanjing, China.
Which VCs invest in companies like Impact Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Impact Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Impact Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.